Developer docs
API playgroundTry for free, no card

Search company profiles

Selexis SA

Full company profile

uuid002u3hr

Namestring
Selexis SA
Legal namestring
Selexis SA
Websiteurl
selexis.com
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Selexis SA is a Belgian life sciences company founded in 2001 and headquartered in Leuven that develops and licenses proprietary cell line development technology for biopharmaceutical manufacturing. Its core offering is the SUREtechnology Platform, a CHO-based cell line development system designed to produce stable, high-yield mammalian cell lines for therapeutic protein and complex biologics production. The platform is built on more than 30 years of cell line development expertise and is positioned as a versatile, scalable, and integrated solution spanning the drug development pipeline from clinical to commercial manufacturing.

The company operates a B2B technology licensing model rather than a direct service business. Selexis generates revenue by embedding its SUREtechnology Platform into the manufacturing workflows of contract development and manufacturing organizations (CDMOs) and biopharmaceutical companies, with disclosed revenue mechanics being licensing fees and royalties. Its most prominent disclosed partner is KBI Biopharma, which features the Selexis technology as a core component of its mammalian cell line development service offering. The company targets biopharmaceutical firms developing complex biologics, using a horizontal segmentation approach across the industry.

Pricing is not publicly disclosed. The source data does not provide headcount, revenue, funding history, ownership structure, or management team details, which limits financial and governance assessment. No AI/ML capabilities, regulatory milestones, M&A activity, or leadership changes are disclosed in the available data.

Short descriptiontext

Selexis SA is a Belgian life sciences company that develops and licenses the SUREtechnology Platform, a proprietary CHO-based cell line development system used by CDMOs and biopharmaceutical companies to produce stable mammalian cell lines for biologics manufacturing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersPlan-les-ouates, Switzerland
HQ citystring
Plan-les-ouates
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
cell line development, biologics manufacturing, CHO cell lines, biopharmaceutical licensing, therapeutic protein production
Industry2 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Medicinal Chemicals & Botanical Products2833
Product category
Cell Line Development Technology / Biopharmaceutical Platform Technology
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Technology Licensing
TypeLicensing Royalties
Description

Selexis generates revenue through licensing its proprietary SUREtechnology Platform to biopharmaceutical companies and CDMOs. The technology is embedded into partners' manufacturing workflows, generating licensing fees and royalties.

kbibiopharma.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Selexis SA develops and licenses its proprietary SUREtechnology Platform, a CHO-based cell line development technology that enables biopharmaceutical companies and CDMOs to generate premium, stable, and integrated mammalian cell lines for the production of complex therapeutic proteins and biologics. The technology is embedded into partner CDMO manufacturing workflows, supporting cell line development from clinical stages through commercial manufacturing.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Selexis SA provides proprietary cell line development technology that is licensed to and integrated into partner CDMOs (Contract Development and Manufacturing Organizations) such as KBI Biopharma. The Selexis® technology platform powers the SUREtechnology Platform™ used by KBI for mammalian cell line development services. The company operates as a technology provider rather than a direct service provider.

Product and service1 record
1SUREtechnology Platform (Selexis® Technology)
CategoryCell Line Development Technology Platform
Description

Proprietary CHO-based cell line development technology platform that provides premium, stable, and integrated mammalian cell lines for the production of complex therapeutic proteins and biologics. Licensed to and embedded within CDMO and biopharmaceutical partner workflows (e.g., KBI Biopharma) to support cell line development from clinical stages through commercial manufacturing.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1KBI Biopharma
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Selexis provides its proprietary SUREtechnology Platform to KBI Biopharma, enabling the CDMO to offer premium, stable, and integrated CHO-based cell line development services. KBI Biopharma features the SUREtechnology Platform as a core component of its mammalian cell line development offerings, supporting the development and manufacturing of complex biologics.

kbibiopharma.com
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Selexis SA

Cell Line Development Technology / Biopharmaceutical Platform Technologyselexis.com

Selexis SA is a Belgian life sciences company that develops and licenses the SUREtechnology Platform, a proprietary CHO-based cell line development system used by CDMOs and biopharmaceutical companies to produce stable mammalian cell lines for biologics manufacturing.

What Selexis SA does

Selexis SA is a Belgian life sciences company founded in 2001 and headquartered in Leuven that develops and licenses proprietary cell line development technology for biopharmaceutical manufacturing. Its core offering is the SUREtechnology Platform, a CHO-based cell line development system designed to produce stable, high-yield mammalian cell lines for therapeutic protein and complex biologics production. The platform is built on more than 30 years of cell line development expertise and is positioned as a versatile, scalable, and integrated solution spanning the drug development pipeline from clinical to commercial manufacturing.

The company operates a B2B technology licensing model rather than a direct service business. Selexis generates revenue by embedding its SUREtechnology Platform into the manufacturing workflows of contract development and manufacturing organizations (CDMOs) and biopharmaceutical companies, with disclosed revenue mechanics being licensing fees and royalties. Its most prominent disclosed partner is KBI Biopharma, which features the Selexis technology as a core component of its mammalian cell line development service offering. The company targets biopharmaceutical firms developing complex biologics, using a horizontal segmentation approach across the industry.

Pricing is not publicly disclosed. The source data does not provide headcount, revenue, funding history, ownership structure, or management team details, which limits financial and governance assessment. No AI/ML capabilities, regulatory milestones, M&A activity, or leadership changes are disclosed in the available data.

Selexis SA firmographics

Firmographics
Name
Selexis SA
Legal name
Selexis SA
Website
https://selexis.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Selexis SA is a Belgian life sciences company that develops and licenses the SUREtechnology Platform, a proprietary CHO-based cell line development system used by CDMOs and biopharmaceutical companies to produce stable mammalian cell lines for biologics manufacturing.
Ownership category
akta.pro rank

Selexis SA industry classification

Industry
Product category
Cell Line Development Technology / Biopharmaceutical Platform Technology
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Cell line development
  • Biologics manufacturing
  • CHO cell lines
  • Biopharmaceutical licensing
  • Therapeutic protein production

Where Selexis SA is headquartered

Location

Headquarters

HQ city
Plan-les-ouates
HQ country
Switzerland
HQ region
Europe

Markets served

Selexis SA business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Technology Licensing: Selexis generates revenue through licensing its proprietary SUREtechnology Platform to biopharmaceutical companies and CDMOs. The technology is embedded into partners' manufacturing workflows, generating licensing fees and royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Selexis SA product offering

Product offering

Core offering

Selexis SA develops and licenses its proprietary SUREtechnology Platform, a CHO-based cell line development technology that enables biopharmaceutical companies and CDMOs to generate premium, stable, and integrated mammalian cell lines for the production of complex therapeutic proteins and biologics. The technology is embedded into partner CDMO manufacturing workflows, supporting cell line development from clinical stages through commercial manufacturing.

Product overview

Selexis SA provides proprietary cell line development technology that is licensed to and integrated into partner CDMOs (Contract Development and Manufacturing Organizations) such as KBI Biopharma. The Selexis® technology platform powers the SUREtechnology Platform™ used by KBI for mammalian cell line development services. The company operates as a technology provider rather than a direct service provider.

Differentiator

Problem solved

Functional benefit

Products and services

  • SUREtechnology Platform (Selexis® Technology) Proprietary CHO-based cell line development technology platform that provides premium, stable, and integrated mammalian cell lines for the production of complex therapeutic proteins and biologics. Licensed to and embedded within CDMO and biopharmaceutical partner workflows (e.g., KBI Biopharma) to support cell line development from clinical stages through commercial manufacturing.

Companies that use Selexis SA

Customer profile

Segments1 record

Ideal customer profiles2 records

Selexis SA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Selexis SA partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • KBI BiopharmacoreStrategic or Co-development PartnerSelexis provides its proprietary SUREtechnology Platform to KBI Biopharma, enabling the CDMO to offer premium, stable, and integrated CHO-based cell line development services. KBI Biopharma features the SUREtechnology Platform as a core component of its mammalian cell line development offerings, supporting the development and manufacturing of complex biologics.

Scale indicators1 record

Recent moves3 records

Expansion highlights1 record

Selexis SA competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

Selexis SA social profiles

Digital presence

Selexis SA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Selexis SA leadership team

Management profile

Number of profiles

Selexis SA funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Selexis SA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Selexis SA

What does Selexis SA do?

Selexis SA develops and licenses its proprietary SUREtechnology Platform, a CHO-based cell line development technology that enables biopharmaceutical companies and CDMOs to generate premium, stable, and integrated mammalian cell lines for the production of complex therapeutic proteins and biologics. The technology is embedded into partner CDMO manufacturing workflows, supporting cell line development from clinical stages through commercial manufacturing.

Is Selexis SA a public or private company?

Selexis SA is a private company. It is classified as unknown and is currently operating.

When was Selexis SA founded?

Selexis SA was founded in 2001. It employs 1,001 to 5,000 people.

Where is Selexis SA based?

Selexis SA is headquartered in Plan-les-ouates, Switzerland, in the Europe region.

How does Selexis SA make money?

One revenue line is on record: technology Licensing.

Does Selexis SA have an API?

No public API is recorded for Selexis SA.

What industry is Selexis SA in?

Selexis SA's product category is Cell Line Development Technology / Biopharmaceutical Platform Technology. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 3254 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AETOSWireKBI Biopharma and Selexis SA Appoint J.D. Mowery as CEOKBI Biopharma and Selexis SA appointed J.D. Mowery as CEO, leveraging his 25-year biotech leadership experience. He will lead both JSR Life Sciences companies into the next generation of CDMOs, with a focus on patient impact and strategic growth within the JSR ecosystem.AETOSWireJSR Life Sciences Announces Operational Consolidation of KBI Biopharma, Inc. and Selexis SA to Operate as one Organization, Providing Seamless Experience for PartnersJSR Life Sciences announced that KBI Biopharma and Selexis SA will consolidate as one organization under the KBI Biopharma name. The combined entity will offer integrated drug development and manufacturing services, with CEO J.D. Mowery leading and Selexis' cell line platform branded as SUREtechnology.BioSpaceKBI Biopharma and Selexis SA Appoint J.D. Mowery as CEOKBI Biopharma and Selexis SA appointed J.D. Mowery as CEO, leveraging his 25-year biotech leadership experience. He will lead the JSR Life Sciences companies into the next generation of CDMOs, with a focus on patient impact and strategic growth.BloombergBiotech Firms Run Away After Industry Party With Topless DancersBiotech and pharma companies distanced themselves from an industry party where topless dancers' bodies bore sponsor logos. Attendees reported a dancer with Selexis SA and Alpha Blue Ocean names painted on her, and one company said continued sponsorship is not an option.GlobeNewswireSelexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy ProgramsSelexis SA and OSE Immunotherapeutics signed two commercial license agreements granting OSE access to Selexis SUREtechnology cell banks. The agreements support clinical development of OSE-172, planned for Phase 1/2 in 2018, and OSE-703, in preclinical studies. This is the third CLA between the partners this year.GlobeNewswireSelexis SA's Marco Bocci Promoted to Vice President European Business DevelopmentSelexis SA promoted Marco Bocci to Vice President of European Licensing and Business Development. He will lead SUREtechnology Platform and SURE CHO-Mplus Libraries licensing efforts for European customers. The company, a biologic drug discovery firm, cited his experience in regulatory affairs and pharmacology.GlobeNewswireSelexis SA to Present New Data and a Case Study at IBC's Cell Line Development and Engineering ConferenceSelexis SA will present new data and a case study at the 10th Annual Cell Line Development and Engineering conference in Berkeley, California, September 8-10, 2014. The presentation covers genome engineering using multiple inserts and co-expression of chaperones to improve recombinant protein production.GlobeNewswireSelexis SA to Showcase Revolutionary Advancements in Protein Expression Technologies at BIO 2014Selexis SA will participate in BIO 2014's One-on-One Partnering Meetings in San Diego, with its CEO presenting 'CHO Genome Engineering for the Generation of CHO Libraries' on June 24. The company's SUREtechnology Platform aims to improve transgene expression in mammalian cells, and representatives will be available for meetings.GlobeNewswireSelexis SA CEO to Speak at the BioProcess Theater at BIO 2014Selexis SA CEO Igor Fisch will present on genome engineering and SURE CHO-Mplus Libraries at the BIO 2014 BioProcess Theater on June 24. The company's platform uses proprietary DNA elements to generate high-level, stable CHO cell lines for recombinant protein production.